HKSTP provides specialized infrastructure for healthtech teams based on their specific validation requirements prior to clinical studies. Early-stage teams conducting foundational R&D should utilize the Biotech Support Centre (BSC) and the Incu-Bio Programme. Innovators in medical technology can engage the Medtech Co-Create platform (MTCC)  to collaborate with healthcare partners and access funding to bring their solutions to the market. For biomedical enterprises advancing toward pre-clinical or early clinical translation, the Clinical Translational Catalyst (CTC)  provides comprehensive regulatory and funding support. Because eligibility requirements vary strictly by program, research teams must consult HKSTP program managers and qualified clinical advisers before initiating study protocols.

Medtech startups can source ecosystem partners and accelerate commercialisation through the Medtech Co-Create programme. This HKSTP initiative connects innovators with medical institutions to facilitate technology integration and end-user clinical testing. Eligible HKSTP tenant companies can access the MTCC Funding Scheme, which provides a designated HK$2 million grant to support the translation of medtech R&D projects. Enterprises should contact the programme team at medtechcocreate@hkstp.org to evaluate project feasibility and funding eligibility.

Biotech startups can access HKSTP's lab space and R&D facilities through two main pathways, depending on their capital readiness: Incu-Bio Programme (For Early-Stage) : Provides financial subsidies, business mentorship, and subsidized workspace for startups needing comprehensive incubation support. Direct Tenancy (For Well-Funded Startups): Companies with sufficient capital can bypass incubation and lease space directly. This allows immediate, pay-as-you-go access to world-class core equipment and in-house scientists at the Biomedical Technology Support Centre (BSC). To explore direct landing options, verify BSC facility availability, or determine the best fit for your R&D needs, contact enquiry.marketing@hkstp.org.

Overseas life and health technology companies establishing a strategic base in Hong Kong can leverage HKSTP’s comprehensive, stage-specific infrastructure. Depending on product maturity, international enterprises can integrate into the ecosystem from discovery to global commercial delivery through three main pathways: Early-Stage R&D: Startups can utilize the Incu-Bio Programme for comprehensive incubation support alongside shared wet laboratories at the Biomedical Technology Support Centre (BSC). Mid-Stage Translation: Teams focused on regulatory clearance, clinical trials, and healthcare partnerships can tap into the Clinical Translational Catalyst (CTC) and the Medtech Co-Create network. Growth-Stage Production: Later-stage companies can scale up using the Advanced Manufacturing Centre (AMC), designed for pilot-scale manufacturing that meets international GMP standards. To determine the best entry route for your product, review the specific programme criteria. For broader location context regarding your expansion, explore HKSTP’s Why Hong Kong and Why China resources prior to submitting your enquiry.

The Medtech Co-Create programme and the Clinical Translational Catalyst (CTC) serve distinctly different stages of healthcare innovation. Medtech Co-Create emphasizes ecosystem collaboration and technology integration, offering a HK$2 million grant for translation projects. Conversely, the CTC Programme provides comprehensive regulatory affairs and clinical trial funding—subsidizing up to 50% of trial expenditures—specifically targeting companies in pre-clinical or early clinical phases. Both pathways require active HKSTP tenancy, and participation does not guarantee clinical study initiation or final regulatory approval.

The HKSTP Incu-Bio Programme provides comprehensive financial aid to eligible biotech startups, offering funding support of up to HK$6 million. Admitted startups also receive preferential access to co-working medical technology laboratories.

The Advanced Manufacturing Centre (AMC), located at the Tseung Kwan O InnoPark, provides a 2.71-hectare, purpose-built production base for high-value biomedical products, wearables, and medical devices. The facility enables healthtech companies to transition from R&D to pilot-scale production under strict international GMP standards. The AMC features state-of-the-art manufacturing processes, stringent testing utilities, and globally integrated smart logistics to facilitate highly customized, low-volume tech innovations.

HKSTP operates the Corporate Venture Fund (CVF), a HKD 1 billion investment fund designed to co-invest with private sector investors in early-to-growth stage technology startups. Since its inception, the CVF has achieved a private capital leverage ratio of approximately 1:13X, supporting over 117 portfolio companies. Startups receive direct venture financing and gain access to an investment community of over 1,000 active investors to facilitate Series A, Series B, and major expansion capital rounds.

Biomedical companies can utilize the GLP Drug Safety Testing Center (DSC) located at the Hong Kong Science Park. Recognized as the first non-academic facility of its kind in Hong Kong, the center accelerates the translation of promising therapeutics toward clinical applications. It provides critical bio-analytics infrastructure and pre-clinical testing capabilities, enabling startups to prepare drug candidates and software models to meet the strict regulatory standards required for human clinical trials.

HKSTP provides extensive pre-IPO advisory services, strategic hospital partnerships, and international ecosystem support for mature companies targeting global market leadership. Capitalizing on Hong Kong's status as a premier global biotech fundraising hub, HKSTP facilitates major public listings on the HKEX. A prominent benchmark includes HKSTP's support of Insilico Medicine, an AI-driven drug discovery enterprise, which successfully executed Hong Kong's largest biotech IPO in 2025, raising HKD 2.28 billion.